COMPANY

Nuclein

HQ: Austin, TX source · nuclein.com ↗ · Southwest

Location: Austin, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $9.25M in debt securities (Form D filed Jun 22, 2026; amended Aug 14, 2026). SEC Form D 0001787352-26-000003 (Jun 22, 2026)
Evidence (1 event)
- Jun 22, 2026 · SEC Form D 0001787352-26-000003
  Name of Issuer: Nuclein, LLC; CIK: 1787352; Address: Austin, TX; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2026-06-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 11114842; Total Amount Sold: 1295000; Federal exemptions: 06b || Name of Issuer: Nuclein, LLC; CIK: 1787352; Address: Austin, TX; Submission type: D/A; Filing date: 2026-08-14; Industry Group: Biotechnology; Date of First Sale: 2026-06-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 16114842; Total Amount Sold: 9253488; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Dec 20, 2024 FDA FDA 510(k) clearance: DASH® SARS-CoV-2 & Flu A/B Test — K241652, Dec 20, 2024. Applicant at approval: Nuclein, LLC. source ↗

Dec 20, 2024 FDA 510(k) clearance: DASH® SARS-CoV-2 & Flu A/B Test — K241652, Dec 20, 2024. Applicant at approval: Nuclein, LLC. source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12